Information for health care professionals
The UK-labelled ERWINASE product is from a global batch and is the same as the Canadian product with respect to composition.
The following differences between the currently approved Canadian and UK labelling should be noted:
TABLE 1 ERWINASE VIAL LABEL
|
Section of the label |
UK |
Canada |
|
Name of Product |
Erwinase® 10,000 Units Lyophilisate for solution for injection
10,000 Units /vial |
Erwinase® 10 000 U.
Sterile freeze-dried powder |
|
Crisantaspase (asparaginase from Erwinia chrysanthemi, Erwinia L-asparaginase) |
Erwinia L-asparaginase |
|
Reconstitution |
Reconstitute before use. |
Dissolve in 1 or 2 mL of Sodium chloride Injection, USP. |
|
Marketing Authorization Holder |
Porton Biopharma Limited
Porton Down
Salisbury
SP4 0JG |
EUSA Pharma SAS |
|
Excipients |
Sodium Chloride,
Glucose Monohydrate |
Not reported on the vial label |
|
Distributor/Local Representative |
Jazz Pharmaceuticals UK Ltd |
CGF Pharmatech Inc.
Montreal Canada |
|
MA number |
PL44403/002 |
DIN 02237815 |
|
Others |
No other information on vial label |
Refer to the enclosed information leaflet |
TABLE 2 BOX LABEL
|
Section |
UK |
Canada |
|
All |
English only |
French Translation |
|
Name of Product |
Erwinase® 10,000 Units Lyophilisate for solution for injection |
Erwinase® 10 000 U.
Sterile freeze-dried powder Antileukemic |
|
Crisantaspase (asparaginase from Erwinia chrysanthemi, Erwinia L-asparaginase) |
Erwinia L-asparaginase for injection |
|
|
Each vial contains:
10,000 Units crisantaspase |
Each vial contains: Erwinia
L-asparaginase 10,000 Units |
|
Marketing Authorization Holder (MAH) |
Porton Biopharma Limited
Porton Down
Salisbury
SP4 0JG |
EUSA Pharma SAS
Limonest, France, 69760 |
|
Excipients |
Sodium Chloride,
Glucose Monohydrate |
Glucose 5.0 mg;
Sodium chloride 0.5 mg |
|
Reconstitution |
Reconstitute before use. |
Dissolve in 1 or 2 mL of Sodium chloride Injection USP.
Gently agitate to dissolve. Use only if clear. |
|
Distributor/Local Representative |
Jazz Pharmaceuticals UK Ltd |
CGF Pharmatech Inc. Montreal Quebec, H4T 1A7 |
|
MA number |
PL44403/002 |
DIN 02237815 |
|
Others |
|
Contains no preservative.
For dosage and directions for use see package insert. |
For complete prescribing information, including Dosage and Administration, please refer to the ERWINASE Canadian Product Monograph (CPM), which is provided with the UK-labelled ERWINASE product, rather than the enclosed UK labelling information. The UK product will be accompanied by this risk communication and the Canadian Product Monograph.
Similarly to the Canadian product, UK-labelled ERWINASE should be reconstituted in 1 to 2 mL of sodium chloride (0.9%) solution for injection. Vials with visible particulate matter anywhere, other than on the underside of the stopper (e.g., on or in the product), before or after reconstitution, should be retained for collection.
Before reconstitution, carefully inspect each vial. If you observe particulate matter anywhere other than on the underside of the stopper (e.g., on or in the product), do not administer the product and retain for collection. If you do not observe particulate matter anywhere, other than on the underside of the stopper, reconstitute the product as usual.
After reconstitution, carefully inspect the reconstituted product. If you discover particulate matter after reconstitution, do not administer the product and retain for collection. If there is no visible particulate matter in the product after reconstitution, as an additional precaution,
use a standard 5-micron filter needle to withdraw the reconstituted UK-labelled product from the vial prior to administration. A study has demonstrated that filtration through a 5-micron filter needle after reconstitution has no effect on ERWINASE activity.
Jazz Pharmaceuticals has assessed the overall benefit to risk ratio of administering ERWINASE for the treatment of acute lymphocytic leukemia as positive, particularly with the additional precaution of using a 5-micron filter needle to withdraw the reconstituted product from the vial.
In the event that you should need to retain a vial of ERWINASE for collection, please contact the Customer Services department for replacement.
Action taken by Health Canada
In light of a potential shortage, Health Canada, per the conditions agreed upon by Jazz Pharmaceuticals, had not objected to importation of UK-labelled ERWINASE Batch 181G. Health Canada will continue to monitor the situation.